Education
About Us
Working with TipRanks
Follow Us
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
ALXO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.40 - $2.05
Previous CloseN/A
Volume579.15K
Average Volume (3M)1.40M
Market Cap
$83.00M
Enterprise Value-$40.95M
Total Cash (Recent Filing)$79.31M
Total Debt (Recent Filing)$3.04M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Nov 06, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding53,551,132
10 Day Avg. Volume835,470
30 Day Avg. Volume1,400,515
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.49
Enterprise Value/Revenue-47.17
Enterprise Value/Gross Profit213.26
Enterprise Value/Ebitda0.35
Forecast
1Y Price Target
$2.00Price Target Upside11.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsThe ultimate goal of the study is to support a biomarker-driven registrational study in HER2+ breast cancer, which could lead to significant advancements in cancer treatment.
Market OpportunityData suggests that 50-70% of HER2+ breast cancer patients overexpress CD47, representing a large market opportunity for ALX Oncology if the study is successful.
Program DevelopmentThe anti-EGFR ADC, ALX2004, remains a high-priority program with significant potential, and the clinical program is on track to begin with the first patient expected to be dosed imminently.
Bears Say
Development Focus ShiftThe ASPEN-CRC trial of Evo in colorectal cancer has been paused to focus development on breast cancer, reflecting a shift in priorities.
Resource AllocationALX has decided not to move forward with the planned Phase 1 ASPEN-CRC study, indicating a need to better prioritize cash resources.
Study Design ChallengesThe single-arm design of the new study may make the data more difficult to interpret compared to the prior plan for a randomized control trial.
ALX Oncology Holdings News
ALXO FAQ
What was ALX Oncology Holdings’s price range in the past 12 months?
ALX Oncology Holdings lowest stock price was $0.40 and its highest was $2.05 in the past 12 months.
What is ALX Oncology Holdings’s market cap?
ALX Oncology Holdings’s market cap is $83.00M.
When is ALX Oncology Holdings’s upcoming earnings report date?
ALX Oncology Holdings’s upcoming earnings report date is Nov 06, 2025 which is in 40 days.
How were ALX Oncology Holdings’s earnings last quarter?
ALX Oncology Holdings released its earnings results on Aug 12, 2025. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.422 by -$0.068.
Is ALX Oncology Holdings overvalued?
According to Wall Street analysts ALX Oncology Holdings’s price is currently Undervalued.
Does ALX Oncology Holdings pay dividends?
ALX Oncology Holdings does not currently pay dividends.
What is ALX Oncology Holdings’s EPS estimate?
ALX Oncology Holdings’s EPS estimate is -0.37.
How many shares outstanding does ALX Oncology Holdings have?
ALX Oncology Holdings has 53,551,132 shares outstanding.
What happened to ALX Oncology Holdings’s price movement after its last earnings report?
ALX Oncology Holdings reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.422. Following the earnings report the stock price went up 6.452%.
Which hedge fund is a major shareholder of ALX Oncology Holdings?
Currently, no hedge funds are holding shares in ALXO
ALX Oncology Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (11.73% Upside)
$2.00 (11.73% Upside)
Blogger Sentiment
Bullish
ALXO Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 96.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $155.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 4.8%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.10%
12-Months-Change
Fundamentals
Return on Equity
-104.21%
Trailing 12-Months
Asset Growth
-55.59%
Trailing 12-Months
Company Description
ALX Oncology Holdings
ALX Oncology Holdings Inc. (ALXO) is a clinical-stage immuno-oncology company focusing on the development of therapies designed to enhance the immune system's ability to eliminate cancer. The company's main product candidate, evorpacept (also known as ALX148), is a CD47-blocking therapeutic aimed at preventing cancer cells from evading the immune system. ALX Oncology operates within the biotechnology and pharmaceutical sectors, targeting various solid tumors and hematologic malignancies.
ALXO Company Deck
ALXO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook with significant advances in clinical programs, especially with the CD47 biomarker-driven strategy that shows promise for targeted oncology approaches. The extension of the cash runway and progress in partnered studies further strengthen the company's position. However, challenges remain in defining specific biomarker cutoffs and addressing unmet needs in HER2-positive breast cancer. Overall, the call suggests optimism for future developments.View all ALXO earnings summariesALXO Stock 12 Month Forecast
Average Price Target
$2.00
▲(11.73% Upside)
Technical Analysis
Ownership Overview
2.81% Insiders
5.49% Mutual Funds
36.67% Other Institutional Investors
52.31% Public Companies and
Individual Investors